Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLT25D1 siRNA
- Development stage
- Preclinical
- Lead developer
- Beijing Ditan Hospital
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
GLT25D1 siRNA is a small interfering RNA (siRNA) therapeutic designed to target and silence the expression of glycosyltransferase 25 domain-containing 1 (GLT25D1), also known as collagen beta(1-O)galactosyltransferase 1 (COLGALT1). GLT25D1 is an enzyme that catalyzes the hydroxylysine O-glycosylation of procollagen, a critical step for collagen triple-helix maturation and secretion. By silencing GLT25D1, the siRNA impairs collagen O-glycosylation, leading to defective procollagen folding, retention within the endoplasmic reticulum (ER), and subsequent ER-associated degradation (ERAD). This structure-oriented approach reduces the secretion of mature collagen and attenuates extracellular matrix remodeling. Developed by researchers at Beijing Ditan Hospital and Capital Medical University, GLT25D1 siRNA (specifically the lead candidate si-D19) is being investigated in preclinical models for the treatment of liver fibrosis.
- Other names
- GLT25D1 small interfering RNAGLT-25D1 small interfering RNAGLT 25D1 small interfering RNA
02
Targets
COLGALT1 (Collagen beta(1-O)galactosyltransferase 1)
Beyond the preview
Go deeper on GLT25D1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLT25D1 siRNA.